MWNA
TERN

Marshall Wace North America’s Terns Pharmaceuticals TERN Stock Holding History

Marshall Wace North America’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,792
Closed -$919K – 1771
2021
Q1 		$919K Buy
+41,792
New +$916K ﹤0.01% 1063

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Marshall Wace North America's TERN Position: Q2 2021 in Review

Marshall Wace North America sold out of Terns Pharmaceuticals (TERN) in Q2 2021, closing a stake of 41,792 shares — an estimated $919K sold.

Marshall Wace North America first reported a position in TERN in Q1 2021 and held it in 1 quarter. The position peaked at $919K in Q1 2021. 36 funds tracked by Wall St. Rank hold TERN as of Q2 2021.

  • Marshall Wace North America reported no remaining Terns Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 41,792 Terns Pharmaceuticals shares in Q2 2021, an estimated $919K.
  • Marshall Wace North America first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Terns Pharmaceuticals position peaked at $919K in Q1 2021.
  • 36 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.